PIP5K1A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3462790	0.54	5/20
SCHEMBL5527006	0.54	5/20
SCHEMBL13446406	0.44	5/20
SCHEMBL6502234	0.78	4/20
SCHEMBL6507449	0.76	4/20
SCHEMBL6505419	0.73	4/20
SCHEMBL6503376	0.73	4/20
SCHEMBL6504079	0.70	4/20
SCHEMBL6510087	0.70	4/20
SCHEMBL6506282	0.68	4/20
SCHEMBL6504356	0.68	4/20
SCHEMBL6530015	0.68	4/20
SCHEMBL6506904	0.54	4/20
Totarol (SCHEMBL285501)	0.50	4/20
Totarol (SCHEMBL1839596)	0.50	4/20
Totarol (SCHEMBL13423504)	0.50	4/20
Totarol (SCHEMBL16238019)	0.50	4/20
Totarol (SCHEMBL30105648)	0.50	4/20
Totarol (SCHEMBL31121504)	0.50	4/20
SCHEMBL6533835	0.46	4/20

Clinical trials — most relevant to PIP5K1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients	PHASE3	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma	nan	RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Clinical Study Evaluating the Effect of Losartan	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PIP5K1A binder may also engage these)

Protein	Name	Similarity
P70181	—	1.000	P70181 →
PIP5K1B	Phosphatidylinositol 4-phosphate 5-kinase type-1 beta	1.000	landscape →
D3ZSI8	—	1.000	D3ZSI8 →
P70182	—	1.000	P70182 →
O70161	—	0.999	O70161 →
Q5CZZ9	—	0.998	Q5CZZ9 →
Q5ZJ58	—	0.997	Q5ZJ58 →
PIP5K1C	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma	0.992	landscape →
Q5I6B8	—	0.991	Q5I6B8 →
Q9SUI2	—	0.990	Q9SUI2 →
Q9M1K2	—	0.988	Q9M1K2 →
Q9W2R3	—	0.988	Q9W2R3 →
Q9SLG9	—	0.988	Q9SLG9 →
Q9C104	—	0.987	Q9C104 →
O48709	—	0.987	O48709 →
Q9LMN1	—	0.986	Q9LMN1 →
O43078	—	0.986	O43078 →
Q9Y7Q7	—	0.986	Q9Y7Q7 →
J9VXM5	—	0.986	J9VXM5 →
Q9C813	—	0.985	Q9C813 →
Q9M149	—	0.985	Q9M149 →
Q6CAP3	—	0.985	Q6CAP3 →
O74788	—	0.985	O74788 →
Q8L850	—	0.985	Q8L850 →
Q22712	—	0.985	Q22712 →
G5EFI8	—	0.985	G5EFI8 →
Q8GS71	—	0.985	Q8GS71 →
F4JX00	—	0.985	F4JX00 →
B3H6Z8	—	0.985	B3H6Z8 →
A0A1D9QMS2	—	0.985	A0A1D9QMS2 →